Future scenarios for the treatment of advanced non-small cell lung cancer: Focus on taxane-containing regimens

Oncologist

Volumn 15, Issue 10, 2010, Pages 1102-1112

  Grossi, Francesco ^a   Kubota, Kaoru ^b   Cappuzzo, Federico ^c   De Marinis, Filippo ^d   Gridelli, Cesare ^e   Aita, Marianna ^f   Douillard, Jean Yves ^g  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

^g CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung carcinoma; Treatment algorithm

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; VASCULOTROPIN; VINCA ALKALOID;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; HUMAN; LARGE CELL CARCINOMA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SINGLE DRUG DOSE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; META-ANALYSIS AS TOPIC; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 77958566257     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0322     Document Type: Article

References (55)

1. Shepherd FA. Chemotherapy for non-small cell lung cancer: Have we reached a new plateau? Semin Oncol 1999;26(suppl 4):3-11.
2. Grossi F, Gridelli C, Aita M et al. Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2008;67:16-26.
3. Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-261.
4. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
5. Schiller JH, Harrington D, Belani C et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
6. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
7. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
8. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003;21:3909-3917.
9. Alberola V, Camps C, ProvencioMet al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer:ASpanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003;21:3207-3213.
10. Kubota K, Nishiwaki Y, Ohashi Y et al. The Four-Arm Cooperative Study (FACS) for advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004;22(suppl 14):616.
11. Douillard JY, Gervais R, Dabouis G et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: Docetaxel-cisplatin versus vinorelbine- cisplatin followed by cross-over to single-agent docetaxel or vinorel-bine at progression: Final results of a randomised phase II study. Ann Oncol 2005;16:81-89.
12. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double- blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
13. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
14. Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: A systematic review and meta-analysis. Br J Cancer 2009;100:436-441.
15. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. The Oncologist 2008; 13(suppl 1):14-20.
16. Rigas JR. Taxane-platinum combinations in advanced non-small cell lung cancer: A review. The Oncologist 2004;9(suppl 2):16-23.
17. Douillard JY, Laporte S, Fossella F et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2:939-946.
18. Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
19. Grossi F, Aita M, Defferrari C et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: A meta-analytical approach. The Oncologist 2009;14:497-510.
20. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007;99: 847-857.
21. Mor V, Stalker MZ, Gralla R et al. Day hospital as an alternative to inpatient care for cancer patients: A random assignment trial. J Clin Epidemiol 1988; 41:771-785.
22. Tiseo M, Martelli O, Mancuso A et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93: 138-144.
23. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
24. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
25. Giovannetti E, Mey V, Nannizzi S et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
26. European Medicines Agency. Alimta: EPAR-Product Information. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000564/WC500025611.pdf, accessed August 28, 2010.
27. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
28. Peterson P, Park K, Fossella F et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma?A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract P2-328]. J Thorac Oncol 2007;2(suppl 4):S851.
29. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
30. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
31. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomized phase 3 trial. Lancet Oncol 2010;11:121-128.
32. European Medicines Agency. Public Assessment Report for Iressa. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/001016/WC500036358.pdf, accessed August 28, 2010.
33. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
34. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/ carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-917.
35. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
36. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27: 1227-1234.
37. Belotti D, Vergani V, Drudis T et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849.
38. Cobo M, Ferrer N, Paredes A et al. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC): Final report. J Clin Oncol 2010; 28(15 suppl): e18009.
39. Patel JD, Hensing TA, RademakerAet al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009;27:3284-3289.
40. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 2003;29:407-415.
41. Grusenmeyer PA, Gralla RJ. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer [abstract 6057]. J Clin Oncol 2006;24(18 suppl):314s.
42. Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium. Nat Rev Drug Discov 2004;3:825-826.
43. Grossi F, Aita M, Follador A et al. Sequential, alternating, and maintenance/ consolidation chemotherapy in advanced NSCLC: A review of the literature. The Oncologist 2007;12:451-464.
44. Hosoe S, Komuta K, Shibata K et al. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer:Amultiinstitutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer 2003;88:342-347.
45. Kubota K, Kawahara M, Ogawara M et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: A randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-1142.
46. Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009;27: 591-598.
47. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcellm lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440.
48. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Alimta® [label]. Approved on 07/02/2009,NDAno. 021462. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf, accessed October 16, 2009.
49. European Medicines Agency. Alimta-H-564-II-15: EPAR-Scientific Discussion- Variation. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion_-_Variation/human/000564/WC500025610.pdf, accessed August 28, 2010.
50. Cappuzzo F, Coudert BP, Wierzbicki R et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: Results from the phase III SATURN study. Presented at the 13th World Conference on Lung Cancer, San Francisco, CA, July 31 - August 4, 2009.
51. Boughton B. New SATURN Results Show Survival Benefit From Erlotinib in NSCLC. Available at http://www.medscape.com/viewarticle/706862, accessed October 16, 2009.
52. U.S. Food and Drug Administration. Tarceva®otinib) [label]. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf, accessed April 25, 2010.
53. European Medicines Agency. Tarceva: EPAR-Assessment Report- Variation. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000618/WC500090680.pdf, accessed August 28, 2010.
54. Soon Y, Stockler MR, Askie LM et al. Duration of chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol 2009;27:3277-3283.
55. Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008;3(suppl 2):S146-S149.